Table 4

The Hospital Anxiety and Depression Scale-Depression (HADS-D) and HADS-Anxiety (HADS-A) count of patients according to severity (normal, mild, moderate or severe) and the difference in severity category between the two assessment points for each arm, prescribing, review and treatment as usual (TAU)*

N*PrescribingN*ReviewN*TAUp Value (between groups†
Baseline HADS-D44Count (%)45Count (%)53Count (%)
 Normal32 (72.7)31 (68.9)38 (71.7)
 Mild8 (18.2)11 (24.4)7 (13.2)
 Moderate3 (6.8)3 (6.7)8 (15.1)
 Severe1 (2.3)00
6-month follow-up HADS-D
 Normal32 (72.7)32 (71.1)32 (60.4)
 Mild7 (15.9)6 (13.3)10 (18.9)
 Moderate5 (11.4)6 (13.3)8 (15.1)
 Severe01 (2.2)3 (5.7)
Difference HADS-D
 ≤–15 (11.4)4 (8.9)2 (3.8)
 034 (77.3)37 (82.0)40 (75.5)
 ≥15 (11.4)4 (8.9)11 (20.8)0.32
p (within groups‡)1.00.710.03 
Baseline HADS-A44Count (%)43Count (%)48Count (%)
 Normal25 (56.8)30 (69.8)29 (60.4)
 Mild8 (18.2)7 (16.3)9 (18.8)
 Moderate8 (18.2)5 (11.6)8 (16.7)
 Severe3 (6.8)1 (2.3)2 (4.2)
6-month follow-up HADS-A
 Normal27 (61.4)29 (67.4)32 (66.7)
 Mild7 (15.9)6 (14.0)5 (10.4)
 Moderate8 (18.2)6 (14.0)10 (20.8)
 Severe2 (4.5)2 (4.7)1 (2.1)
Difference HADS-A
 ≤–16 (13.6)3 (7.0)10 (20.8)
 035 (79.5)33 (76.7)29 (60.4)
 ≥13 (6.8)7 (16.3)9 (18.8)0.14
 p (within groups‡)0.250.210.55 
  • Within-arm and between-arm p values are also reported.

  • *Number of participants in each group who completed the appropriate part of the HADS at both baseline and follow-up.

  • †From χ² test on difference in HADS.

  • ‡From marginal homogeneity test.